Mease P, et al. - The impact of subcutaneous (s.c.) secukinumab (an interleukin-17A inhibitor) on clinical signs and symptoms and radiographic progression in subjects having psoriatic arthritis (PsA) was assessed by the authors. Results suggested that in subjects with PsA, the clinical signs and symptoms were improved significantly by s.c. secukinumab (300 mg and 150 mg) with and without loading dose (LD), moreover, it inhibited radiographic structural progression relative to placebo at week 24.